George Perry to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications George Perry has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.452
-
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit. Ageing Res Rev. 2024 08; 99:102348.
Score: 0.132
-
Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis? J Alzheimers Dis. 2023; 92(3):799-801.
Score: 0.120
-
Making the Case for Accelerated Withdrawal of Aducanumab. J Alzheimers Dis. 2022; 87(3):1003-1007.
Score: 0.112
-
Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. Arch Med Res. 2012 Nov; 43(8):694-8.
Score: 0.059
-
The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes. J Alzheimers Dis. 2023; 94(2):497-507.
Score: 0.030